icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
WCPXwMu5QK2jDnW2
Listen
